CN107279865A - A kind of maca oyster dietary product and preparation method thereof - Google Patents
A kind of maca oyster dietary product and preparation method thereof Download PDFInfo
- Publication number
- CN107279865A CN107279865A CN201610196774.5A CN201610196774A CN107279865A CN 107279865 A CN107279865 A CN 107279865A CN 201610196774 A CN201610196774 A CN 201610196774A CN 107279865 A CN107279865 A CN 107279865A
- Authority
- CN
- China
- Prior art keywords
- oyster
- maca
- parts
- dietary product
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000237502 Ostreidae Species 0.000 title claims abstract description 58
- 235000020636 oyster Nutrition 0.000 title claims abstract description 58
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 52
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 52
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 52
- 235000005911 diet Nutrition 0.000 title claims abstract description 33
- 230000000378 dietary effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000007787 solid Substances 0.000 claims abstract description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000463 material Substances 0.000 claims abstract description 22
- 238000003756 stirring Methods 0.000 claims abstract description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 11
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 11
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000811 xylitol Substances 0.000 claims abstract description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 11
- 229960002675 xylitol Drugs 0.000 claims abstract description 11
- 235000010447 xylitol Nutrition 0.000 claims abstract description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 6
- 229940088417 precipitated calcium carbonate Drugs 0.000 claims abstract description 5
- 238000009501 film coating Methods 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 238000007873 sieving Methods 0.000 abstract 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000035900 sweating Effects 0.000 description 6
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- 229930003779 Vitamin B12 Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000036299 sexual function Effects 0.000 description 3
- 238000009492 tablet coating Methods 0.000 description 3
- 239000002700 tablet coating Substances 0.000 description 3
- 235000019163 vitamin B12 Nutrition 0.000 description 3
- 239000011715 vitamin B12 Substances 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a kind of maca oyster dietary product and preparation method thereof, belongs to dietary product technical field, is made by the maca of 10~30 parts by weight, the oyster of 15~20 parts by weight and with auxiliary material.A kind of preparation method of maca oyster dietary product, comprises the following steps：Each component is taken, crushes, sieves for subsequent use；Maca, oyster, maltodextrin, precipitated calcium carbonate, xylitol and 1~5 part of ethanol after crushing are weighed by weight, is mixed, and sieving obtains solid base；2.0~8.6 parts of solid base is weighed, 1~5 part 50% of ethanol solution is added and stirs to obtain wet grain, dry, obtain dry particl；Dry particl and remaining solid base are mixed, magnesium stearate and silica is added, stirred, sieving, tabletting is produced.The present invention is combined with two kinds of functional components, enhances assimilation effect, improves the bioavilability of maca and special oyster.And preparation technology is simple, can retain maca and the mixed active ingredient of oyster.
Description
Technical field
The present invention relates to dietary product technical field, more particularly to a kind of maca oyster dietary product and its preparation
Method.
Background technology
There is following chemical composition composition in maca：Protein content is that more than 10%, carbohydrate is
59%th, fiber 8.5%；Containing abundant zinc, calcium, iron, titanium, rubidium, potassium, sodium, copper, manganese, magnesium, strontium,
The mineral matters such as phosphorus, iodine, and contain vitamin C, B1, B2, B6, A, E, B12 and B5；Fat
Content is not high but is wherein generally unrighted acid, and the content of linoleic acid plus linolenic acid is up to more than 53%, naturally
Active ingredient includes alkaloid, glucosinolate and its catabolite benzyl isothiocyanate, sterol, Polyphenols thing
Matter etc.；Also have macamides (macamides) He Maka dilute (macaenes) in addition, and determine both things
Confrontation balanced human's hormone secretion has remarkable effect, the natural hormone engine so agate card is otherwise known as.
Oyster has high nutrition and medical value, wherein the oyster per 100g, Zn content is up to 9.39mg,
Male can just meet demand of the body to zinc for edible one daily；Contained abundant Taurine has bright in oyster
Aobvious hepatic cholagogic effect, this is also the good medicine for preventing and treating pregnancy period functional condition in intrahepatic cholestasis；Contained is abundant micro
Element and glycogen, to promoting the growing of fetus, rescuing pregnant woman anemia；Oyster is the preferably food replenished the calcium again
Product, it is phosphorous very abundant, due to being needed when calcium is by body absorption；Oyster also contains vitamin B12, and this is one
As lacking in food, the cobalt element in vitamin B12 is that the indispensable material of anaemia institute is disliked in prevention, because
And oyster have enliven hematopoiesis；There are a variety of excellent amino acid, these ammonia in contained protein in oyster
Base acid has detoxication, can remove internal noxious material, and tarine therein has reduction blood courage again
The effect of sterol concentration, therefore can prevention of arterial hardening；Oyster extract, which has, substantially suppresses platelet aggregation work
With, TXA2 contents in the blood fat and blood of high fat of blood patient can be reduced, are conducive to insulin secretion and utilization,
Malignant cell can again strengthened radiation-sensitive, and it is grown has inhibitory action.The food of oyster
Have transquilization with heavy material with effect, checking exuberance of yang tonifying yin, softening and resolving hard mass is restrained astringent or styptic treatment for spontaneous sweating.For insomnia of palpitating with fear, dizziness ear
Band is collapsed in ring, scrofula subcutaneous nodule, note of the ancient Chinese lump in the abdomen lump in the abdomen, spontaneous sweating, seminal emission, pantothenic acid of having a stomachache；Calcined oyster shell convergence is astringent or styptic treatment for spontaneous sweating,
For spontaneous sweating, band is collapsed in seminal emission, acid regurgitation of having a stomachache；Beneficial the moon checking exuberance of yang, for it is irritated caused by hyperactivity of yang due to yin deficiency,
Insomnia, dizziness headache, one's ears rang and spots danced before one's eyes, hectic fever night sweat；Convergence is astringent or styptic treatment for spontaneous sweating, under treatment abnormal sweating, band, passes out semen；
Softening and resolving hard mass, can treat and tie swollen, enclosed mass, convulsive seizure due to phlegm-fire scrofula.
Wherein maca improves fertility, improves sexual function, anticancer, anti-leukocythemia, treatment climacteric metancholia
Deng effect is as current study hotspot and has obtained universal checking, developed countries and regions are made
Most popular daily of the such as U.S., Japan, Singapore, Canada, Hong Kong, Macao, TaiWan, China etc.
Health food.But it is low all to deposit bioavilability, inconvenience is drunk in carrying, and human intake's amount is few to wait not enough, because
This is necessary integration of drinking and medicinal herbs theory and diet-therapy health-preserving theory according to the traditional Chinese medical science, and developing a kind of suitable people needs
It is wanting, can improve bioavilability, instant, new type functional modernization industry processing balance
Human body hormone secretion dietary product.
The content of the invention
The invention provides a kind of maca oyster dietary product and preparation method thereof, the guarantor of existing maca is solved
The problem of health food bioavilability is low.
In order to solve the above technical problems, the technical solution adopted by the present invention is：
A kind of maca oyster dietary product, is maca by 10~30 parts by weight, the oyster of 15~20 parts by weight
It is made with auxiliary material.
Wherein it is preferred to, the formulation of the dietary product is tablet, capsule or granule.
Wherein it is preferred to, the formulation of the dietary product is tablet, and the auxiliary material includes following weight parts
Component：2.1~25.5 parts of maltodextrin, 8~20.1 parts of precipitated calcium carbonate, 10~25 parts of xylitol, magnesium stearate
0.2~2 part, 0.1~1.4 part of silica.
A kind of preparation method of maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 60~300 mesh sieves are crossed, it is standby；
(2) maca after crushing, oyster, maltodextrin, precipitated calcium carbonate, xylitol are weighed by weight
With 1~5 part 50% of ethanol, cross 60~150 mesh sieves after being well mixed and solid base is made；
(3) 2.0~8.6 parts of solid base is weighed, the ethanol solution for adding 1~5 part 50% stirs
Wet grain；
(4) the wet grain is dried into 30~60min under the conditions of 30 DEG C~60 DEG C, relative humidity 10%~40%
Dry particl is made；
(5) dry particl and remaining solid base are mixed, add magnesium stearate and silica,
Stir and 20~40 mesh sieves are crossed after 30min, tabletting is produced.
Wherein it is preferred to, the step of also including film coating after the step (5).
Beneficial effects of the present invention：
This product is using maca and oyster as main composition, preferred other customary adjuvants, and having for obtaining changes
The dietary product of philanthropist's body hormone secretion.Two kinds of functional components are combined, and enhance assimilation effect, are improved again
Maca and the bioavilability of special oyster.And preparation technology is simple, can retain maca and oyster is mixed
Effective coordination composition；The excellent efficacy of food can be played, with regulation body immunity, improve sexual function,
Enrich blood and adjust the health-care efficacies such as blood, anti-oxidant, enhancing sexual function, anti-aging；Good health care effect, no pair
Effect.
Embodiment
The technical scheme in the embodiment of the present invention is clearly and completely described below, it is clear that described
Embodiment be only a part of embodiment of the invention, rather than whole embodiment.Based in the present invention
Embodiment, it is every other that those of ordinary skill in the art are obtained under the premise of creative work is not made
Embodiment, belongs to the scope of protection of the invention.
A kind of maca oyster dietary product, is maca by 10~30 parts by weight, the oyster of 15~20 parts by weight
It is made with auxiliary material.
A kind of preparation method of maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 60~300 mesh sieves are crossed, it is standby；
(2) maca after crushing, oyster, maltodextrin, precipitated calcium carbonate, xylitol are weighed by weight
With 1~5 part 50% of ethanol, cross 60~150 mesh sieves after being well mixed and solid base is made；
(3) 2.0~8.6 parts of solid base is weighed, the ethanol solution for adding 1~5 part 50% stirs
Wet grain；
(4) the wet grain is dried into 30~60min under the conditions of 30 DEG C~60 DEG C, relative humidity 10%~40%
Dry particl is made；
(5) dry particl and remaining solid base are mixed, add magnesium stearate and silica,
Stir and 20~40 mesh sieves are crossed after 30min, tabletting is produced.
Embodiment 1
The present embodiment provides a kind of maca oyster dietary product, is maca, 18 parts by weight by 20 parts by weight
Oyster and it is made with auxiliary material.
The preparation method of the maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 100 mesh sieves are crossed, it is standby；
(2) 20 parts of maca after crushing, 18 parts of oyster, 15 parts of maltodextrin, lightweight carbon are weighed by weight
The ethanol of sour 15 parts of calcium, 20 parts and 3 part 50% of xylitol, crosses 100 mesh sieves after being well mixed and solid base is made；
(3) 5.0 parts of solid base is weighed, 3 part 50% of ethanol solution is added and stirs to obtain wet grain；
(4) the wet grain is dried into 45min under the conditions of 45 DEG C, relative humidity 10%~40% and is made dry
Grain；
(5) dry particl and remaining solid base are mixed, adds 1.0 parts of magnesium stearate and titanium dioxide
30 mesh sieves are crossed after 0.8 part of silicon, stirring 30min, tabletting is produced.
(6) 1 part of film coating material is weighed, it is 10% that the film coating material is made into concentration with 60% ethanol
Coating solution, after by compress tablet coating 150min, coating pan rotating speed 5r/min is controlled during coating, atomizing pressure is
0.7MPa。
Embodiment 2
The present embodiment provides a kind of maca oyster dietary product, is maca, 12 parts by weight by 15 parts by weight
Oyster and it is made with auxiliary material.
The preparation method of the maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 300 mesh sieves are crossed, it is standby；
(2) 15 parts of maca after crushing, 12 parts of oyster, 2.1 parts of maltodextrin, lightweight carbon are weighed by weight
The ethanol of sour 20.1 parts of calcium, 10 parts and 5 part 50% of xylitol, crosses 150 mesh sieves after being well mixed and solid base is made；
(3) 8.6 parts of solid base is weighed, 5 part 50% of ethanol solution is added and stirs to obtain wet grain；
(4) the wet grain is dried into 30min under the conditions of 60 DEG C, relative humidity 40% and dry particl is made；
(5) dry particl and remaining solid base are mixed, adds 2 parts of magnesium stearate and titanium dioxide
40 mesh sieves are crossed after 0.1 part of silicon, stirring 30min, tabletting is produced.
Embodiment 3
The present embodiment provides a kind of maca oyster dietary product, is maca, 20 parts by weight by 10 parts by weight
Oyster and it is made with auxiliary material.
The preparation method of the maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 60 mesh sieves are crossed, it is standby；
(2) 10 parts of maca, 20 parts of oyster, 25.5 parts of maltodextrin, lightweight after crushing are weighed by weight
The ethanol of 8 parts of calcium carbonate, 25 parts and 1 part 50% of xylitol, crosses 60~150 mesh sieves after being well mixed and solid is made
Base-material；
(3) 2.0 parts of solid base is weighed, 1 part 50% of ethanol solution is added and stirs to obtain wet grain；
(4) the wet grain is dried into 30min under the conditions of 30 DEG C, relative humidity 10% and dry particl is made；
(5) dry particl and remaining solid base are mixed, adds 0.2 part of magnesium stearate and titanium dioxide
40 mesh sieves are crossed after 1.4 parts of silicon, stirring 30min, tabletting is produced.
(6) 1 part of film coating material is weighed, the film coating material is made into concentration with 50% ethanol is
7%% coating solution, after by compress tablet coating 180min, during coating control coating pan rotating speed 6r/min, atomization
Pressure is 1MPa.
Embodiment 4
The present embodiment provides a kind of maca oyster dietary product, is maca, 16 parts by weight by 15 parts by weight
Oyster and it is made with auxiliary material.The preparation method of the maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 100 mesh sieves are crossed, it is standby；
(2) 15 parts of maca after crushing, 16 parts of oyster, 3 parts of maltodextrin, lightweight carbon are weighed by weight
The ethanol of sour 15 parts of calcium, 13 parts and 2 part 50% of xylitol, crosses 60~150 mesh sieves after being well mixed and solid is made
Base-material；
(3) 6.0 parts of solid base is weighed, 3 part 50% of ethanol solution is added and stirs to obtain wet grain；
(4) the wet grain is dried into 50min under the conditions of 40 DEG C, relative humidity 25% and dry particl is made；
(5) dry particl and remaining solid base are mixed, adds 0.8 part of magnesium stearate and titanium dioxide
30 mesh sieves are crossed after 1.2 parts of silicon, stirring 30min, tabletting is produced.
(6) 1 part of film coating material is weighed, it is 12% that the film coating material is made into concentration with 70% ethanol
Coating solution, after by compress tablet coating 120min, coating pan rotating speed 5r/min is controlled during coating, atomizing pressure is
0.3MPa。
Embodiment 5
The present embodiment provides a kind of maca oyster dietary product, is maca, 18 parts by weight by 25 parts by weight
Oyster and it is made with auxiliary material.
The preparation method of the maca oyster dietary product, comprises the following steps：
(1) each component is taken, is crushed, 100 mesh sieves are crossed, it is standby；
(2) 25 parts of maca after crushing, 18 parts of oyster, 21 parts of maltodextrin, lightweight carbon are weighed by weight
The ethanol of sour 10 parts of calcium, 21 parts and 4 part 50% of xylitol, crosses 100 mesh sieves after being well mixed and solid base is made；
(3) 4.0 parts of solid base is weighed, 4 part 50% of ethanol solution is added and stirs to obtain wet grain；
(4) the wet grain is dried into 40min under the conditions of 350 DEG C, relative humidity 25% and dry particl is made；
(5) dry particl and remaining solid base are mixed, adds 1.4 parts of magnesium stearate and titanium dioxide
30 mesh sieves are crossed after 0.7 part of silicon, stirring 30min, tabletting is produced.
The Application Example of the maca oyster dietary product of the present invention：
Dietary product instructions of taking of the present invention, consumption：Orally, 3 times a day, (specification that 2 tablets once：0.5g/
Piece), it is within every 45 days a course for the treatment of.
In 100 clinics, wherein：The people of sex dysfunction patient 50；There is 48 people's symptoms after one course for the treatment of
It is obviously improved, remaining 2 people takes after a course for the treatment of effectively again.
Immunologic function is low：25 people, effective 10 people of a course for the treatment of；It is effective after remaining 15 people, two course for the treatment of.
Lassitude, it is short of physical strength (" inferior health " state)：25 people, effective 19 people of a course for the treatment of；Two
Effective 6 people after the individual course for the treatment of.
Do not find obvious adverse reaction and toxic side effect during observing.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in this hair
Within bright spirit and principle, any modification, equivalent substitution and improvements made etc. should be included in this hair
Within bright protection domain.
Claims (5)
1. a kind of maca oyster dietary product, it is characterised in that be by 10~30 parts by weight maca, 15~20
The oyster of parts by weight and it is made with auxiliary material.
2. a kind of maca oyster dietary product according to claim 1, it is characterised in that the dietotherapy production
The formulation of product is tablet, capsule or granule.
3. a kind of maca oyster dietary product according to claim 2, it is characterised in that the dietotherapy production
The formulation of product is tablet, and the auxiliary material includes following components in parts by weight：2.1~25.5 parts of maltodextrin, gently
8~20.1 parts of matter calcium carbonate, 10~25 parts of xylitol, 0.2~2 part of magnesium stearate, 0.1~1.4 part of silica.
4. a kind of preparation method of the maca oyster dietary product described in claim 3, it is characterised in that including with
Lower step：
(1) each component is taken, is crushed, 60~300 mesh sieves are crossed, it is standby；
(2) maca after crushing, oyster, maltodextrin, precipitated calcium carbonate, xylitol are weighed by weight
With 1~5 part 50% of ethanol, cross 60~150 mesh sieves after being well mixed and solid base is made；
(3) 2.0~8.6 parts of solid base is weighed, the ethanol solution for adding 1~5 part 50% stirs
Wet grain；
(4) the wet grain is dried into 30~60min under the conditions of 30 DEG C~60 DEG C, relative humidity 10%~40%
Dry particl is made；
(5) dry particl and remaining solid base are mixed, add magnesium stearate and silica,
Stir and 20~40 mesh sieves are crossed after 30min, tabletting is produced.
5. a kind of preparation method of maca oyster dietary product according to claim 4, it is characterised in that
The step of also including film coating after the step (5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610196774.5A CN107279865A (en) | 2016-03-31 | 2016-03-31 | A kind of maca oyster dietary product and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610196774.5A CN107279865A (en) | 2016-03-31 | 2016-03-31 | A kind of maca oyster dietary product and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107279865A true CN107279865A (en) | 2017-10-24 |
Family
ID=60087619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610196774.5A Pending CN107279865A (en) | 2016-03-31 | 2016-03-31 | A kind of maca oyster dietary product and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107279865A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110651996A (en) * | 2018-08-01 | 2020-01-07 | 马晨光 | Food for nourishing and improving kidney function and preparation method thereof |
| CN115581300A (en) * | 2018-08-20 | 2023-01-10 | 北京姿美堂生物技术有限公司 | Composition for relieving fatigue and enhancing immunity and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08294374A (en) * | 1995-04-27 | 1996-11-12 | Higami Suisan:Kk | Oyster-processed food product |
| CN103961469A (en) * | 2014-05-23 | 2014-08-06 | 汤臣倍健股份有限公司 | Traditional Chinese medicinal composition and application thereof, healthy product and preparation method thereof |
| CN104872649A (en) * | 2015-04-27 | 2015-09-02 | 广州市炜鑫生物科技有限公司 | Medical and edible homologous maca food and preparation method thereof |
-
2016
- 2016-03-31 CN CN201610196774.5A patent/CN107279865A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08294374A (en) * | 1995-04-27 | 1996-11-12 | Higami Suisan:Kk | Oyster-processed food product |
| CN103961469A (en) * | 2014-05-23 | 2014-08-06 | 汤臣倍健股份有限公司 | Traditional Chinese medicinal composition and application thereof, healthy product and preparation method thereof |
| CN104872649A (en) * | 2015-04-27 | 2015-09-02 | 广州市炜鑫生物科技有限公司 | Medical and edible homologous maca food and preparation method thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110651996A (en) * | 2018-08-01 | 2020-01-07 | 马晨光 | Food for nourishing and improving kidney function and preparation method thereof |
| CN115581300A (en) * | 2018-08-20 | 2023-01-10 | 北京姿美堂生物技术有限公司 | Composition for relieving fatigue and enhancing immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102293276B (en) | Liver-clearing vision-improving health-care tea | |
| CN102742840A (en) | Maca Cordyceps buccal tablet and preparation method thereof | |
| CN106552105A (en) | A kind of effervescent tablet of enhancing immunity and preparation method thereof | |
| CN105126067A (en) | Composition for reducing uric acid and application thereof | |
| CN103952278A (en) | Maca mineral spring wine and production method for same | |
| WO2018077311A1 (en) | Composition for relieving eye strain and preparation method therefor | |
| KR20130056780A (en) | Cosmetic composition comprising soapnut | |
| CN103989045A (en) | Brown sugar composition for menstrual period and application thereof | |
| CN106668507A (en) | Medicine for curing male infertility and preparation method thereof | |
| US20170209486A1 (en) | Health-care preparation simultaneously with magnesium supplement and antioxidant functions and preparation method thereof | |
| CN107279865A (en) | A kind of maca oyster dietary product and preparation method thereof | |
| EP2184069A1 (en) | Natural alcohol detoxication treatment, gradual weaning with long-term complete abstinence. | |
| CN102028230B (en) | Health care product auxiliary material and application thereof | |
| CN103798434A (en) | Health care tea bag as well as preparation method thereof | |
| CN107156820A (en) | Conditioning women postpartum is damaged nutraceutical of constitution and preparation method thereof comprehensively | |
| CN104382002A (en) | Maca tablet for alleviating fatigue | |
| CN104872649A (en) | Medical and edible homologous maca food and preparation method thereof | |
| CN109744543A (en) | A kind of bone collagen peptide composite powder and preparation method thereof | |
| CN108315177A (en) | A kind of medicine-food two-purpose hides careless Tibetan medicine assembled alcoholic drinks and preparation method thereof | |
| CN108041229A (en) | A kind of summer Traditional Chinese medicine health tea of invigorating spleen and nourishing heart | |
| CN108450964A (en) | Treat and prevent the health composition and preparation method thereof of female menstrual period syndrome | |
| CN107233491A (en) | It is a kind of to improve the antifatigue maca composition of energy | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN103815348A (en) | Dahurian rose fruit yin-nourishing and dryness-moistening hot-pot condiment | |
| CN105214068B (en) | A kind of alimentation composition and preparation method thereof for treating Tourette syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171024 |
|
| RJ01 | Rejection of invention patent application after publication |